^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    Signatera™

    Company:
    Natera
    Type:
    CE Marked
    Related tests:
    Evidence Level:
    Resistant: C4 – Case Studies

    [MSI-H/dMMR + PD-L1 expression-Triple Negative Breast Cancer-atezolizumab]

    Source:
    SITC 2020
    Test:

    Signatera™

    Title:
    Line of therapy adjustment in a patient with advanced triple-negative breast cancer (TNBC) by using personalized ctDNA test for treatment response monitoring
    Published date:
    11/09/2020
    Excerpt:
    Separate analyses indicated MSI-high and PD-L1 positive tumor status, leading to the initiation of the first line of therapy (nab-paclitaxel and Atezolizumab)….Given non-responsiveness with the first-line therapy, the patient was initiated with sacituzumab govitecan....Continued monitoring of ctDNA demonstrated ctDNA levels <5MTM/mL for a period of two months before serially rising again (to 89.27 MTM/ml). PET-CT ordered in response to increasing ctDNA levels confirmed progression involving hepatic and lung lesions.
    Secondary therapy:
    albumin-bound paclitaxel
    DOI:
    10.1136/jitc-2020-SITC2020.0025
    Evidence Level:
    Resistant: C4 – Case Studies

    [MSI-H/dMMR + PD-L1 expression-Triple Negative Breast Cancer-sacituzumab govitecan-hziy]

    Source:
    SITC 2020
    Test:

    Signatera™

    Title:
    Line of therapy adjustment in a patient with advanced triple-negative breast cancer (TNBC) by using personalized ctDNA test for treatment response monitoring
    Published date:
    11/09/2020
    Excerpt:
    Separate analyses indicated MSI-high and PD-L1 positive tumor status, leading to the initiation of the first line of therapy (nab-paclitaxel and Atezolizumab)….Given non-responsiveness with the first-line therapy, the patient was initiated with sacituzumab govitecan....Continued monitoring of ctDNA demonstrated ctDNA levels <5MTM/mL for a period of two months before serially rising again (to 89.27 MTM/ml). PET-CT ordered in response to increasing ctDNA levels confirmed progression involving hepatic and lung lesions.
    DOI:
    10.1136/jitc-2020-SITC2020.0025